Investment
Features
FeesSafety
Academy
More
Pluang+

Compare IDEXX Laboratories, Inc. (IDXX) vs Tenet Healthcare Corporation (THC) Price & Performance

IDEXX Laboratories, Inc.Trade
Tenet Healthcare CorporationTrade

Price performance (Past 24H)

Key statistics

IDEXX Laboratories, Inc. vs Tenet Healthcare Corporation — how do they compare? IDEXX Laboratories, Inc. trades at $572.23 (market cap $46.22B), while Tenet Healthcare Corporation trades at $262 (market cap $20.89B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.2× Tenet Healthcare Corporation's market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.

IDXXTHC
Market Cap
$46.22B$20.89B
Sector
HealthHealth
52-Week High
$766.68$262.63
52-Week Low
$526.44$161.37
Enterprise Value
$47.12B$31.97B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.

Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.

Tenet Healthcare Corporation

Tenet Healthcare (THC) trades at $260.67, up 0.28% today, with strong technical momentum including a golden cross pattern and bullish moving average alignment. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $6.12 versus $4.26 forecast, maintaining a three-quarter earnings beat streak. Valuation metrics remain attractive with P/E of 10.03 and EV/EBITDA of 5.73, while profitability metrics show exceptional ROE of 53.31% and net margin of 9.9%.

The investment outlook remains positive with 81% analyst buy ratings and $281.44 consensus price target representing 8% upside. Key risks include policy headwinds in ACA exchanges and hospital segment challenges, though strong ambulatory growth provides offset. The stock presents a compelling value-growth combination with momentum characteristics, supported by institutional accumulation and positive earnings revisions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX

About Tenet Healthcare Corporation

Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.

Read more on THC